Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats

AA Martinez, A Pisanu, MA Paquette, A Seillier… - Neurobiology of …, 2015 - Elsevier
Long-term administration of l-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …
被引用次数：66 相关文章
[HTML] nih.gov

[HTML][HTML] ACTIVATION OF PPAR GAMMA RECEPTORS REDUCES LEVODOPA-INDUCED DYSKINESIAS IN 6-OHDA-LESIONED RATS

AA Martinez, MG Morgese, A Pisanu… - Neurobiology of …, 2015 - ncbi.nlm.nih.gov
Long-term administration of L-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats

AA Martinez, MG Morgese, A Pisanu… - NEUROBIOLOGY OF …, 2015 - fair.unifg.it
Long-term administration of l-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats

AA Martinez, MG Morgese, A Pisanu… - Neurobiology of …, 2015 - pubmed.ncbi.nlm.nih.gov
Long-term administration of l-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats

AA Martinez, MG Morgese, A Pisanu, T Macheda… - Neurobiology of …, 2015 - infona.pl
Long-term administration of l-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …
[PDF] academia.edu

[PDF][PDF] ACTIVATION OF PPAR GAMMA RECEPTORS REDUCES LEVODOPA-INDUCED DYSKINESIAS IN 6-OHDA-LESIONED RATS

AA Martinez, MG Morgese, A Pisanu, T Macheda… - Neurobiol Dis, 2015 - academia.edu
Long-term administration of L-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats

AA Martinez, MG Morgese, A Pisanu… - Neurobiology of …, 2015 - experts.umn.edu
Long-term administration of l-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

AA Martinez, MG Morgese, A Pisanu… - Neurobiology of …, 2014 - europepmc.org
Long-term administration of L-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats

AA Martinez, MG Morgese, A Pisanu… - Neurobiology of …, 2015 - scholars.uthscsa.edu
Long-term administration of l-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats

A Martinez, M Morgese, A Pisanu, T Macheda… - NEUROBIOLOGY OF …, 2015 - iris.unica.it
Long-term administration of l-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …